Document Detail


Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
MedLine Citation:
PMID:  23320989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Cariprazine is an atypical antipsychotic in clinical development for the treatment of schizophrenia and bipolar mania/mixed episodes.
AREAS COVERED: The purpose of this review is to describe the chemistry, pharmacodynamic profile, pharmacokinetics, and clinical profile of cariprazine.
EXPERT OPINION: Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist. Doses ≥ 1.5 mg/d yielded 69 - 75% D2/D3 receptor occupancy as measured in positron emission tomography scans. Mean half-life for cariprazine was 2 - 5 d over a dose range of 1.5 - 12.5 mg. Cariprazine produces two clinically relevant metabolites: desmethyl-cariprazine and didesmethyl-cariprazine, the latter having a longer half-life than cariprazine. Exposure to didesmethyl-cariprazine exceeded that of the parent drug. Cariprazine is metabolized by CYP3A4 and to a lesser extent by CYP2D6. The efficacy and safety of cariprazine have been so far investigated only in a few short-term (unpublished) clinical trials; however, three studies in schizophrenia and three studies in bipolar mania/mixed episodes evidenced a statistically significant therapeutic effect compared to placebo for cariprazine at doses ranging from 1.5 to 12 mg/d. There does not appear to be clinically relevant adverse effects of cariprazine on metabolic variables. Commonly encountered adverse events associated with cariprazine include insomnia, extrapyramidal symptoms, akathisia, sedation, nausea, dizziness, and constipation.
Authors:
Leslie Citrome
Related Documents :
24063549 - Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal ...
24187619 - Neurological adverse effects in patients of advanced colorectal carcinoma treated with ...
1331179 - Verapamil ameliorates the clinical and pathological course of murine myocarditis.
17609909 - Clinical observation on chemical damage of nephron and the preventive and therapeutic e...
17277429 - Effect of feeding type on the efficacy of phototherapy.
142179 - Immune complex disease. vi. some determinants of the varieties of glomerular lesions in...
3828169 - High- and low-dose fentanyl anaesthesia: circulatory and plasma catecholamine responses...
11037739 - Headache characteristics during the development of tolerance to nitrates: pathophysiolo...
12016119 - Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  9     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-16     Completed Date:  2013-10-17     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  193-206     Citation Subset:  IM    
Affiliation:
New York Medical College, Valhalla, NY, USA. citrome@cnsconsultant.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antipsychotic Agents / adverse effects,  chemistry,  metabolism*,  therapeutic use*
Clinical Trials as Topic / methods,  trends
Humans
Piperazines / adverse effects,  chemistry,  metabolism*,  therapeutic use*
Schizophrenia / drug therapy*,  metabolism*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Piperazines; F6RJL8B278/cariprazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Super-Reduced Diferrous [2Fe-2S] Cluster.
Next Document:  A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.